Unknown

Dataset Information

0

Semimechanistic Population Pharmacokinetic Model to Predict the Drug-Drug Interaction Between S-ketamine and Ticlopidine in Healthy Human Volunteers.


ABSTRACT: Low-dose oral S-ketamine is increasingly used in chronic pain therapy, but extensive cytochrome P450 (CYP) mediated metabolism makes it prone to pharmacokinetic drug-drug interactions (DDIs). In our study, concentration-time data from five studies were used to develop a semimechanistic model that describes the ticlopidine-mediated inhibition of S-ketamine biotransformation. A mechanistic model was implemented to account for reversible and time-dependent hepatic CYP2B6 inactivation by ticlopidine, which causes elevated S-ketamine exposure in vivo. A pharmacokinetic model was developed with gut wall and hepatic clearances for S-ketamine, its primary metabolite norketamine, and ticlopidine. Nonlinear mixed effects modeling approach was used (NONMEM version 7.3.0), and the final model was evaluated with visual predictive checks and the sampling-importance-resampling procedure. Our final model produces biologically plausible output and demonstrates that ticlopidine is a strong inhibitor of CYP2B6 mediated S-ketamine metabolism. Simulations from our model may be used to evaluate chronic pain therapy with S-ketamine.

SUBMITTER: Ashraf MW 

PROVIDER: S-EPMC6202471 | biostudies-other | 2018 Oct

REPOSITORIES: biostudies-other

altmetric image

Publications

Semimechanistic Population Pharmacokinetic Model to Predict the Drug-Drug Interaction Between S-ketamine and Ticlopidine in Healthy Human Volunteers.

Ashraf Muhammad W MW   Peltoniemi Marko A MA   Olkkola Klaus T KT   Neuvonen Pertti J PJ   Saari Teijo I TI  

CPT: pharmacometrics & systems pharmacology 20180910 10


Low-dose oral S-ketamine is increasingly used in chronic pain therapy, but extensive cytochrome P450 (CYP) mediated metabolism makes it prone to pharmacokinetic drug-drug interactions (DDIs). In our study, concentration-time data from five studies were used to develop a semimechanistic model that describes the ticlopidine-mediated inhibition of S-ketamine biotransformation. A mechanistic model was implemented to account for reversible and time-dependent hepatic CYP2B6 inactivation by ticlopidine  ...[more]

Similar Datasets

| S-EPMC9305550 | biostudies-literature
| S-EPMC7033406 | biostudies-literature
| S-EPMC7266304 | biostudies-literature
| S-EPMC7557955 | biostudies-literature
| S-EPMC3561686 | biostudies-literature
| S-EPMC8275530 | biostudies-literature
| S-EPMC10789188 | biostudies-literature
| S-EPMC6063220 | biostudies-literature
| S-EPMC5595943 | biostudies-literature
| S-EPMC8865872 | biostudies-literature